Drug Trial Radar · NCT03945292
Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
Last checked: Nov 19, 2026Latest source record: Nov 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
40
Actual
Start
Aug 7, 2019
Primary completion
Nov 8, 2021
Study completion Sep 18, 2023
Sponsor
- Lead sponsor
- Arrowhead PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- May 10, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of AROAAT2001 (SEQUOIA) is to evaluate the safety, efficacy and tolerability of multiple doses of the investigational product, Fazirsiran Injection, administered subcutaneously to participants with alpha-1 antitrypsin deficiency (AATD).
Conditions
- Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran InjectionDrug
solution for subcutaneous (sc) injection
PlaceboOther
sterile normal saline (0.9% NaCl), calculated to match active comparator, for sc injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Serum Z-Alpha-1 Antitrypsin (Z-AAT) at Week 16Time frame: Baseline, Week 16 (+/- 2 weeks)
Locations
21 sites in 6 countries. Site status is shown where the registry gives one.
Research Site 5
Birmingham, Alabama
Research Site 9
Phoenix, Arizona
Research Site 14
La Jolla, California
Research Site 17
Los Angeles, California
Research Site 11
Sacramento, California
Research Site 15
San Francisco, California
Research Site 13
Stanford, California
Research Site 2
Gainesville, Florida
Research Site 7
Indianapolis, Indiana
Research Site 3
Iowa City, Iowa
Research Site 10
St Louis, Missouri
Research Site 12
New York, New York
Research Site 1
Charleston, South Carolina
Research Site 4
Nashville, Tennessee
Research Site 19
Houston, Texas
Research Site 16
Salt Lake City, Utah
Research Site 27
Aachen, Germany
Research Site 22
Pavia, Italy
Research Site 23
Leiden, Netherlands
Research Site 24
Funchal, Portugal
Research Site 20
Barcelona, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.